...
首页> 外文期刊>BMC Anesthesiology >Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure
【24h】

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure

机译:在接受心脏手术的儿童和失代偿性心力衰竭儿童中使用左西孟旦的单中心经验

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room. We present the largest single-center experience of levosimendan in children. Methods Retrospective analysis of all children who received levosimendan infusions between July 5, 2001 and July 4, 2010 in a pediatric intensive care unit. The results of a questionnaire for physicians (anesthesiologist/intensivists, cardiologists and cardiac surgeons) concerning their clinical perceptions of levosimendan are evaluated Results During the study period a total of 484 infusions were delivered to 293 patients 53% of whom were male. The median age of the patients was 0.4 years (4 hours-21.1 years) at the time of levosimendan administration. A majority of levosimendan infusions were administered to children who were undergoing cardiac surgery (72%), 14% to children with cardiomyopathy and 14% to children with cardiac failure. Eighty-nine out of the 293 patients (30.4%) received repeated doses of levosimendan (up to 11 infusions). The most common indication for the use of levosimendan (94%) was when the other inotropic agents were insufficient to maintain stable hemodynamics. Levosimendan was especially used in children with cardiomyopathy (100%) or with low cardiac output syndrome (94%). A majority (89%) of the respondents believed that levosimendan administration postponed the need for mechanical assist devices in some children with cardiomyopathy. Moreover, 44% of respondents thought that the mechanical support was totally avoided in some patients undergoing cardiac surgery after receiving levosimendan. Conclusion Levosimendan is widely used in our institution and many physicians believe that its use could decrease the need for mechanical support in children undergoing cardiac surgery or in children with decompensated heart failure. However, there is a lack of good empirical evidence in children to support this perception.
机译:背景技术左西孟旦具有优于常规静脉正性肌力药的药理和血液动力学优势。它主要在儿科重症监护室或手术室中用作急救药物。我们介绍了儿童左西孟旦最大的单中心体验。方法回顾性分析2001年7月5日至2010年7月4日在儿科重症监护室接受左西孟旦输注的所有儿童。评估了针对医师(麻醉师/强化医师,心脏病专家和心脏外科医师)对左西孟旦的临床看法的问卷调查结果。结果在研究期间,共向293名患者输送了484例输液,其中53%是男性。左西孟旦给药时患者的中位年龄为0.4岁(4小时至21.1岁)。左西孟旦的大部分输注量用于接受心脏手术的儿童(72%),患有心肌病的儿童14%和患有心力衰竭的儿童14%。 293名患者中有89名(30.4%)接受了重复剂量的左西孟旦治疗(最多11次输注)。使用左西孟旦最常见的指征(94%)是当其他正性肌力药不足以维持稳定的血流动力学时。左西孟旦特别用于患有心肌病(100%)或低心输出量综合征(94%)的儿童。大多数(89%)的受访者认为,左西孟旦的给药推迟了某些患有心肌病的儿童对机械辅助装置的需求。此外,有44%的受访者认为在接受左西孟旦后接受心脏手术的某些患者中完全避免了机械支持。结论左西孟旦已在我们的机构中​​广泛使用,许多医生认为,左西孟旦的使用可减少接受心脏手术的儿童或失代偿性心力衰竭儿童的机械支持。但是,儿童缺乏良好的经验证据来支持这种看法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号